About: Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 22 May 2008

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2008 (uk) im Mai 2008 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 22 May 2008 (en) artículu científicu espublizáu en mayu de 2008 (ast)
publication date	wds:Q81337520-26E9CC6F-A6D1-4695-AD7D-11F7828F9EFA
publication date	2008-05-22 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q81337520-B55FD890-54A9-4289-BF43-349FA114F6E2
language of work or name	English
author name string	wds:Q81337520-06142A56-FF2A-49A9-AB7B-9CF8D089EAB9 wds:Q81337520-34A94820-9287-4B18-AD30-7C73E5E99968 wds:Q81337520-75796DAF-67C0-45FF-B5DE-3E8166A2B652 wds:Q81337520-A20598B6-AF62-427A-8027-B3E81CFC6BD7 wds:Q81337520-CFC87670-476E-4B85-8728-0A6703909DD8 wds:Q81337520-D306157C-8037-4E26-9F14-2CBEDB7AE36B wds:Q81337520-DEA061A9-04D9-441F-B4C4-9F525CF6D595
author name string	J L Miller Y-C Yang M Hooper B Strober C Teller P Yamauchi F Dann
rdfs:label	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis (en) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis (nl)
skos:prefLabel	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis (en) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis (nl)
name	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis (en) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis (nl)
title	wds:Q81337520-4722A3B2-82E7-4070-9211-5570449C4943
title	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis (en)
page(s)	wds:Q81337520-9D3B5AF0-7F72-41F8-A5D1-72A4068FBF61
page(s)	322-330
instance of	wds:Q81337520-36E560FD-36F3-4DCC-89DE-6F70214D6E5C
instance of	scholarly article
main subject	wds:Q81337520-216810BB-084A-43B9-87B4-A595EF8BF3F2
main subject	psoriatic arthritis
PubMed ID	wds:Q81337520-1CF7C739-B77E-4007-BD5C-0CC78D67130E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18503600
PubMed ID	18503600
published in	wds:Q81337520-C080DA8C-C47F-4518-9CFE-87F4A24655A9
published in	British Journal of Dermatology
issue	wds:Q81337520-04832C4C-1D7B-4AC9-9C6A-24BBF977B0B3
volume	wds:Q81337520-03532E5B-DBB7-4AC0-A5C7-DD486369D719
issue	2
volume	159
DOI	wds:Q81337520-32480F65-1484-4BC0-927C-6784F0A35E91
DOI	http://dx.doi.org/10.1111/J.1365-2133.2008.08628.X
DOI	10.1111/J.1365-2133.2008.08628.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81337520
is cites work of	Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk The impact of psoriasis on pregnancy outcomes Cardiometabolic risk in psoriasis: differential effects of biologic agents Update on biomarkers in psoriatic arthritis C-reactive protein and uric Acid levels in patients with psoriasis The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood Does treatment of psoriasis reduce the risk of cardiovascular disease? Psoriasis is not a useful independent risk factor for cardiovascular disease Moesin and stress-induced phosphoprotein-1 are possible sero-diagnostic markers of psoriasis Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis Managing comorbid disease in patients with psoriatic arthritis Recent advances in neutralizing the IL-6 pathway in arthritis. C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B. Psoriasis and Cardiovascular Risk-Do Promising New Biomarkers Have Clinical Impact? Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms How can psoriatic arthritis be diagnosed early? A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1 Hit hard and early: Can the march of psoriasis be halted? Evaluation of serum adenosine deaminase and inflammatory markers in psoriatic patients Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients Lack of association between the genetic variations in the C-reactive protein gene and the risk of psoriasis among the Taiwanese The effect of biological agent treatment on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, and C-reactive protein in psoriasis patients
is cites work of	wds:Q38178202-A88C9797-6985-49CF-AF61-C3BF674509CF wds:Q37768710-DB5BA584-CFF0-4DAC-B12B-30B00E44A00C wds:Q37145684-C956713F-299B-459B-9CF8-4187D5332908 wds:Q39201687-5D058737-E448-469F-958B-52F3EA828768 wds:Q41693144-BF95526E-B386-4101-9FA8-5D9D59938EF3 wds:Q37741049-34414A0A-236E-4AFB-9EB6-6D3BBD0B1FBA wds:Q46180528-74F99776-CEB4-484D-9B42-63D3C1C27489 wds:Q83240744-FB3E80EA-57D0-4BF6-BA74-89A98BC8910F wds:Q36479450-816CFDBB-C6D1-40F3-BBC8-8EDD78070B1A wds:Q38266480-128D56ED-1A47-46D5-A179-45A9DA3B8AC5 wds:Q47120280-C44A3314-D9EA-425C-980D-A8FAA22F3D7E wds:Q84108844-B091512F-5864-4E01-BF42-840C04BE6458 wds:Q84945095-7493E74F-BE98-42CC-8B2C-259D0233D10E wds:Q33882485-65C9A760-27B3-4E27-9C80-51DE5B403FF0 wds:Q41848576-58D2A23E-D59F-4AB5-AA1B-36ECAED70354 wds:Q42420342-A8613781-A0C0-4BC4-9376-FE8FCE3AA244 wds:Q64289124-9ABDF16D-1345-4F11-BB52-9DF6CB3BDB73 wds:Q89174152-270040B0-23D7-457E-937B-EA5A14F8D47F wds:Q37673703-DEEC0DE5-15BD-4584-80E3-4CAD732DB824

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software